share_log

Atara Biotherapeutics-临床前结果支持将 ATA3219 推向对 B 细胞驱动型自身免疫性疾病患者的临床评估

Atara Biotherapeutics-Preclinical Results Support Advancing ATA3219 to Clinical Evaluation in Patients with B-Cell-Driven Autoimmune Diseases

Zhitong Finance ·  May 30 04:04
Atara Biotherapeutics-Preclinical Results Support Advancing ATA3219 to Clinical Evaluation in Patients with B-Cell-Driven Autoimmune Diseases

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment